Celiac Disease Market Outlook 2031 Features Growth in Oral and Parenteral Treatment Routes and Increasing Homecare Adoption

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2031"

The Global Celiac Disease Market is estimated to reach over USD 1,195.5 Mn by 2031, exhibiting a CAGR of 9.8% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2874

Celiac disease is a chronic autoimmune disorder precipitated by the ingestion of gluten, a protein present in wheat, rye, and barley. Upon gluten exposure, the immune system initiates an inflammatory response that damages the lining of the small intestine, specifically the villi, which are essential for nutrient absorption. This damage impairs the body's ability to absorb key nutrients-such as proteins, fats, carbohydrates, vitamins, and minerals-potentially leading to malnutrition if left untreated.

The global celiac disease market is witnessing significant growth, fueled by rising disease prevalence, increasing public awareness, and continuous advancements in diagnostic technologies. Notable market trends include higher diagnosis rates, the proliferation of gluten-free food products, and ongoing research into targeted therapeutic interventions. Key growth drivers encompass improved diagnostic accuracy, growing adoption of gluten-free dietary habits, and expanding availability of disease-specific solutions.

Despite this positive trajectory, the market encounters several obstacles, such as underdiagnosis, limited public knowledge, and stringent regulatory frameworks governing gluten-free product labeling and compliance. Market segmentation by diagnostic modality, treatment type, end-user profile, and geographical distribution facilitates the implementation of focused commercial strategies. To meet the evolving needs of this patient population, stakeholders have opportunities to invest in the development of advanced diagnostics, innovative treatment modalities, and high-quality gluten-free alternatives. With increasing global awareness and a rising emphasis on disease management, the celiac disease market is expected to continue its upward momentum.

List of Prominent Players in the Celiac Disease Market:
• Amgen
• Anokion SA
• BioLineRx Ltd
• ChemoCentryx, Inc
• COUR Pharmaceutical
• F. Hoffmann-La Roche Ltd
• ImmunogenX, LLC
• Innovate Biopharmaceuticals
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The growth of the global celiac disease market is primarily driven by the increasing prevalence of the condition, which has led to heightened demand for gluten-free dietary products and therapeutic interventions. Rising consumer awareness regarding the health implications of gluten consumption is further accelerating market expansion. While many individuals receive formal diagnoses, a significant portion of the population is adopting gluten-free diets due to greater public understanding of gluten sensitivity and its associated risks. In addition, advancements in diagnostic methodologies have facilitated earlier and more accurate identification of celiac disease, contributing to a growing diagnosed patient base. The expanded availability of gluten-free options across retail and foodservice sectors has also supported adherence to prescribed dietary regimens, further propelling market growth.

Challenges:
Despite favorable growth prospects, the market faces several challenges that may restrict its advancement. The elevated cost of gluten-free products remains a considerable barrier, limiting accessibility for some patient populations. Persistent underdiagnosis, particularly in regions with low disease awareness, continues to hinder comprehensive disease management. Moreover, compliance with stringent food labeling and safety regulations presents operational complexities for gluten-free product manufacturers. In emerging markets, limited distribution infrastructure and product availability also constrain market penetration and affect patient adherence to gluten-free dietary requirements.

Regional Trends:
North America currently holds the largest share of the celiac disease market, supported by a high prevalence of the condition, robust healthcare expenditure, and the presence of leading market participants. The United States is the key contributor to regional growth. Meanwhile, the Asia-Pacific region is projected to exhibit a strong compound annual growth rate (CAGR) through 2032, fueled by increasing awareness, improved healthcare infrastructure, and expanding population bases. Within this region, China accounts for the highest market share, while India is emerging as the fastest-growing market, driven by rising diagnosis rates and increased consumer health consciousness.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2874

Recent Developments:
• In June 2021, BioLineRx announced the start of a Phase 2b clinical trial for its flagship drug, BL-7010, as a therapy for celiac disease. The experiment will assess the safety and efficacy of BL-7010 in lowering gluten-induced symptoms and gut inflammation in celiac disease patients.
• In September 2022, ChemoCentryx recently announced encouraging results from a Phase 2 clinical trial of a new medication candidate for celiac disease-associated refractory sprue. The study found that refractory sprue, a severe form of celiac disease, showed encouraging results in terms of symptom reduction and intestinal health.

Segmentation of Celiac Disease Market-
By Treatments-
• Infliximab
• Larazotide Acetate
• Gluten-Free Diet
• Others
By Route of Administration-
• Oral
• Parenteral
By End-Users-
• Hospitals
• Homecare
• Others
By Distribution Channels-
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/celiac-disease-market/2874

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.